类风湿关节炎患者对SARS-CoV-2疫苗接种的体液和T细胞应答
该观察性研究纳入120例已按阿根廷国家卫生部策略接种SARS-CoV-2疫苗的类风湿关节炎患者,评估两剂接种后的体液和T细胞应答。第二剂后81.7%出现抗SARS-CoV-2抗体,70.0%有中和活性,65.3%有特异性T细胞应答;BBIBP-CorV及阿巴西普、利妥昔单抗治疗与抗体不可测和无中和活性相关。
要点
- 第二剂后81.7%患者出现抗SARS-CoV-2抗体,70.0%有中和活性,65.3%有特异性T细胞应答。
- BBIBP-CorV及阿巴西普、利妥昔单抗治疗与两剂后抗体不可测和无中和活性相关。
- BBIBP-CorV还与T细胞应答缺失相关,其不良事件总发生率显著较低(166.7事件/1000剂,P<0.02)。
核心结论
- 在该接种同源和异源COVID-19疫苗方案的类风湿关节炎队列中,10例患者中2例未产生抗SARS-CoV-2 IgG,70%有中和活性,65%有特异性T细胞应答。
- BBIBP-CorV使用与体液和细胞应答不足相关,阿巴西普和利妥昔单抗治疗导致抗SARS-CoV-2 IgG形成和中和活性受损。
研究设计与样本
- 观察性研究,纳入120例≥18岁并按阿根廷国家卫生部疫苗接种策略接种SARS-CoV-2疫苗的类风湿关节炎患者。
- 在第一剂和第二剂后评估抗SARS-CoV-2 IgG抗体(ELISA-COVIDAR检测)、中和活性(VERO细胞毒性)和特异性T细胞应答(IFN-γ ELISpot检测)。
主要发现
- 多数使用同源方案,包括Gam-COVID-Vac(27.5%)、ChAdOx1(24.2%)和BBIBP-CorV(22.5%);最常见组合为Gam-COVID-Vac/mRNA-1273(21.7%)。
- 第二剂后81.7%出现抗SARS-CoV-2抗体,70.0%有中和活性,65.3%有特异性T细胞应答。
- BBIBP-CorV使用及阿巴西普和利妥昔单抗治疗与两剂后抗体不可测和无中和活性相关。
- BBIBP-CorV还与T细胞应答缺失相关。
- 不良事件总发生率为357.1事件/1000剂,BBIBP-CorV显著较低(166.7事件/1000剂,P<0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to assess the SARS-CoV-2-specific humoral and T cell response after a two-dose regimen of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA). METHODS: In this observational study, patients with RA who are ≥18 years of age and vaccinated for SARS-CoV-2 according to the Argentine National Health Ministry's vaccination strategy were included. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies (ELISA-COVIDAR test), neutralizing activity (cytotoxicity in VERO cells), and specific T cell response (IFN-γ ELISpot Assay) were assessed after the first and second dose. RESULTS: A total of 120 patients with RA were included. Mostly, homologous regimens were used, including Gam-COVID-Vac (27.5%), ChAdOx1 (24.2%), and BBIBP-CorV (22.5%). The most frequent combination was Gam-COVID-Vac/mRNA-1273 (21.7%). After the second dose, 81.7% presented with anti-SARS-CoV-2 antibodies, 70.0% presented with neutralizing activity, and 65.3% presented with specific T cell response. The use of BBIBP-CorV and treatment with abatacept (ABA) and rituximab (RTX) were associated with undetectable antibodies and no neutralizing activity after two doses. BBIBP-CorV was also associated with the absence of T cell response. The total incidence of adverse events was 357.1 events per 1,000 doses, significantly lower with BBIBP-CorV (166.7 events per 1,000 doses, P < 0.02). CONCLUSION: In this RA cohort vaccinated with homologous and heterologous regimens against COVID-19, 2 out of 10 patients did not develop anti-SARS-CoV-2 IgG, 70% presented with neutralizing activity, and 65% presented with specific T cell response. The use of BBIBP-CorV was associated with deficient humoral and cellular response, whereas treatment with ABA and RTX resulted in an impaired anti-SARS-CoV-2 IgG formation and neutralizing activity.
引用
- Isnardi CA, Landi M, Cruces L, et al. Humoral and T Cell Response to SARS-CoV-2 Vaccination in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2023. PMID: 37605835. doi:10.1002/acr.25221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。